Lexaria Bioscience Corp.
Lexaria Bioscience Corp.

Lexaria Bioscience Corp.'s proprietary drug delivery technology, DehydraTECH™, improves the way active pharmaceutical ingredients (APIs) enter the bloodstream by promoting healthier ingestion methods and increasing the effectiveness of fat-soluble active molecules, thereby lowering overall dosing. The Company’s technology can be applied to many different ingestible product formats, including foods, beverages, oral suspensions, tablets, and capsules. DehydraTECH increases bio-absorption by up to 5-10x, reduces time of onset from 1 - 2 hours to 10 - 20 minutes, and masks unwanted tastes for orally administered bioactive molecules, including anti-virals, cannabinoids, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs), nicotine, and other molecules. Lexaria has licensed DehydraTECH to multiple companies including a world-leading tobacco producer for the development of smokeless, oral-based nicotine products and for use in industries that produce cannabinoid beverages, edibles, and oral products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide.
Lexaria Bioscience Corp. (LXX)
SEDAR Information
Company Info
Capitalization
Company Officers
News Releases
Lexaria Appoints new Board Member
Lexaria Closes US$11M Public Offering
Bulletins
2021-0112 –Consolidation - Lexaria Bioscience Corp. (LXX)
Le 11 janvier/January 2021
Lexaria Bioscience Corp. has announced a consolidation of its issued and outstanding common shares. At the rate of one (1) new share for each thirty (30) shares held.
The consolidation will be effected at 4:30 p.m. (EST) on January 11, 2021 with the shares trading on a post-consolidated basis on January 12, 2021.
Upon completion of the split, there will be approximately 3,001,476 shares issued and outstanding.
Advertisement
Publicité